3.18
전일 마감가:
$3.24
열려 있는:
$3.2
하루 거래량:
331.94K
Relative Volume:
0.18
시가총액:
$3.15M
수익:
$12.99M
순이익/손실:
$-23.72M
주가수익비율:
-0.0327
EPS:
-97.2514
순현금흐름:
$-23.28M
1주 성능:
-37.37%
1개월 성능:
-41.67%
6개월 성능:
-96.86%
1년 성능:
-99.17%
Aptevo Therapeutics Inc Stock (APVO) Company Profile
명칭
Aptevo Therapeutics Inc
전화
206-838-0500
주소
2401 4TH AVE., SEATTLE, WA
APVO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
APVO
Aptevo Therapeutics Inc
|
3.19 | 3.15M | 12.99M | -23.72M | -23.28M | -97.25 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.35 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.33 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.23 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
559.88 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.89 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2018-11-05 | 개시 | Ladenburg Thalmann | Buy |
2017-10-05 | 재개 | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc 주식(APVO)의 최신 뉴스
Top Small Cap Stocks Worth WatchingJune 18th - MarketBeat
Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga
Aptevo Therapeutics raises $8 million in registered direct offering - Investing.com Australia
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Aptevo Therapeutics (APVO) Secures $8M Through Direct Offering - GuruFocus
Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double - MSN
Aptevo Therapeutics raises $8 million in registered direct offering By Investing.com - Investing.com India
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday?Aptevo Therapeutics (NASDAQ:APVO) - Benzinga
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules | APVO Stock News - GuruFocus
An early stage 85% remissions rate in AML drives Aptevo’s stock surge - BioWorld MedTech
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire
Aptevo Secures $8M Funding: Biotech Company Accelerates Cancer Drug Development Pipeline - Stock Titan
Aptevo Therapeutics stock soars after impressive AML treatment results - Investing.com
Aptevo Therapeutics stock soars after impressive AML treatment results By Investing.com - Investing.com Canada
Why did Aptevo Therapeutics Shares Skyrocket in Premarket Trading Today? - Tokenist
Aptevo Therapeutics Skyrockets on Game-Changing AML Drug News - RagingBull
Aptevo reports 85% remission rate in frontline AML trial By Investing.com - Investing.com Nigeria
Aptevo Therapeutics (APVO) Shows Promising Results in RAINIER Tr - GuruFocus
Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell - MarketScreener
Aptevo Therapeutics (APVO) Shows Promising Results in AML Trial - GuruFocus
Aptevo Therapeutics announces new clinical data from RAINIER trial - TipRanks
Aptevo announces clinical data from ongoing Phase 1b/2 RAINIER trial - TipRanks
Breakthrough AML Drug Achieves 85% Remission Rate: New Hope for Previously Untreatable Patients - Stock Titan
Aptevo Therapeutics Signs Equity Purchase Agreement - TipRanks
APVO Secures Roth Capital Partners as Exclusive Placement Agent - GuruFocus
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Decreases By 55.0% - Defense World
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High - MSN
Aptevo Participating in the BIO International Convention | APVO Stock News - GuruFocus
Aptevo Sends Business Development Team to BIO 2025: Major Partnership Opportunities Ahead - Stock Titan
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus
Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus
Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks
Aptevo Therapeutics Announces Reverse Stock Split - TipRanks
Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus
Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus
Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire
Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa
APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus
APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus
Aptevo reports high remission in AML patients with new drug - Investing.com Australia
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire
Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan
Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Aptevo Therapeutics Inc (APVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):